Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Research Report 2025(Status and Outlook)

March 2025 | 217 pages | ID: GF6B780EBC6BEN
Bosson Research

Abstracts

Report Overview

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

This report provides a deep insight into the global Drugs for Duchenne Muscular Dystrophy (DMD) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Drugs for Duchenne Muscular Dystrophy (DMD) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Drugs for Duchenne Muscular Dystrophy (DMD) market in any manner.

Global Drugs for Duchenne Muscular Dystrophy (DMD) Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Sarepta Therapeutics

PTC Therapeutics

Pfizer

Bristol-Myers Squibb

Italfarmaco

Santhera Pharmaceuticals

WaVe life Science

Market Segmentation (by Type)

Eteplirsen

Deflazacort

Ataluren

Market Segmentation (by Application)

Hospitals

Clinics

Home Care

Geographic Segmentation

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Drugs for Duchenne Muscular Dystrophy (DMD) Market
• Overview of the regional outlook of the Drugs for Duchenne Muscular Dystrophy (DMD) Market:

Key Reasons to Buy this Report:

• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Drugs for Duchenne Muscular Dystrophy (DMD) Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Drugs for Duchenne Muscular Dystrophy (DMD)
1.2 Key Market Segments
1.2.1 Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Type
1.2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Overview
2.1 Global Market Overview
2.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Competitive Landscape
3.1 Company Assessment Quadrant
3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Product Life Cycle
3.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Manufacturers (2020-2025)
3.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Manufacturers (2020-2025)
3.5 Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Drugs for Duchenne Muscular Dystrophy (DMD) Average Price by Manufacturers (2020-2025)
3.7 Manufacturers Drugs for Duchenne Muscular Dystrophy (DMD) Manufacturing Sites, Area Served, Product Type
3.8 Drugs for Duchenne Muscular Dystrophy (DMD) Market Competitive Situation and Trends
3.8.1 Drugs for Duchenne Muscular Dystrophy (DMD) Market Concentration Rate
3.8.2 Global 5 and 10 Largest Drugs for Duchenne Muscular Dystrophy (DMD) Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Chain Analysis
4.1 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Drugs for Duchenne Muscular Dystrophy (DMD) Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 Global Trade Frictions and Their Impacts to Drugs for Duchenne Muscular Dystrophy (DMD) Market
5.7 ESG Ratings of Leading Companies
6 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market by Region
6.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region
6.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region
6.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Region
6.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
6.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
6.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region
7 North America Market Overview
7.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
7.1.1 USA Market Overview
7.1.2 Canada Market Overview
7.1.3 Mexico Market Overview
7.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
7.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
8 Europe Market Overview
8.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
8.1.1 Germany Market Overview
8.1.2 France Market Overview
8.1.3 U.K. Market Overview
8.1.4 Italy Market Overview
8.1.5 Spain Market Overview
8.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
8.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
9 Asia-Pacific Market Overview
9.1 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
9.1.1 China Market Overview
9.1.2 Japan Market Overview
9.1.3 South Korea Market Overview
9.1.4 India Market Overview
9.1.5 Southeast Asia Market Overview
9.2 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
9.3 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
10 South America Market Overview
10.1 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
10.1.1 Brazil Market Overview
10.1.2 Argentina Market Overview
10.1.3 Columbia Market Overview
10.2 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
10.3 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
11 Middle East and Africa Market Overview
11.1 Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
11.1.1 Saudi Arabia Market Overview
11.1.2 UAE Market Overview
11.1.3 Egypt Market Overview
11.1.4 Nigeria Market Overview
11.1.5 South Africa Market Overview
11.2 Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
11.3 Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
12 Drugs for Duchenne Muscular Dystrophy (DMD) Market Production by Region
12.1 Global Production of Drugs for Duchenne Muscular Dystrophy (DMD) by Region(2020-2025)
12.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Region (2020-2025)
12.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2020-2025)
12.4 North America Drugs for Duchenne Muscular Dystrophy (DMD) Production
12.4.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Production Growth Rate (2020-2025)
12.4.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2020-2025)
12.5 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production
12.5.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production Growth Rate (2020-2025)
12.5.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2020-2025)
12.6 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production (2020-2025)
12.6.1 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production Growth Rate (2020-2025)
12.6.2 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2020-2025)
12.7 China Drugs for Duchenne Muscular Dystrophy (DMD) Production (2020-2025)
12.7.1 China Drugs for Duchenne Muscular Dystrophy (DMD) Production Growth Rate (2020-2025)
12.7.2 China Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2020-2025)
13 Drugs for Duchenne Muscular Dystrophy (DMD) Market Segmentation by Type
13.1 Evaluation Matrix of Segment Market Development Potential (Type)
13.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Type (2020-2033)
13.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Type (2020-2033)
13.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Price by Type (2020-2033)
14 Drugs for Duchenne Muscular Dystrophy (DMD) Market Segmentation by Application
14.1 Evaluation Matrix of Segment Market Development Potential (Application)
14.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Sales by Application (2020-2033)
14.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Application (2020-2033)
14.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Growth Rate by Application (2020-2033)
15 Key Companies Profile
15.1 Sarepta Therapeutics
15.1.1 Sarepta Therapeutics Basic Information
15.1.2 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
15.1.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
15.1.4 Sarepta Therapeutics Business Overview
15.1.5 Sarepta Therapeutics SWOT Analysis
15.1.6 Sarepta Therapeutics Recent Developments
15.2 PTC Therapeutics
15.2.1 PTC Therapeutics Basic Information
15.2.2 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
15.2.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
15.2.4 PTC Therapeutics Business Overview
15.2.5 PTC Therapeutics SWOT Analysis
15.2.6 PTC Therapeutics Recent Developments
15.3 Pfizer
15.3.1 Pfizer Basic Information
15.3.2 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
15.3.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
15.3.4 Pfizer Business Overview
15.3.5 Pfizer SWOT Analysis
15.3.6 Pfizer Recent Developments
15.4 Bristol-Myers Squibb
15.4.1 Bristol-Myers Squibb Basic Information
15.4.2 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
15.4.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
15.4.4 Bristol-Myers Squibb Business Overview
15.4.5 Bristol-Myers Squibb Recent Developments
15.5 Italfarmaco
15.5.1 Italfarmaco Basic Information
15.5.2 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
15.5.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
15.5.4 Italfarmaco Business Overview
15.5.5 Italfarmaco Recent Developments
15.6 Santhera Pharmaceuticals
15.6.1 Santhera Pharmaceuticals Basic Information
15.6.2 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
15.6.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
15.6.4 Santhera Pharmaceuticals Business Overview
15.6.5 Santhera Pharmaceuticals Recent Developments
15.7 WaVe life Science
15.7.1 WaVe life Science Basic Information
15.7.2 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
15.7.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
15.7.4 WaVe life Science Business Overview
15.7.5 WaVe life Science Recent Developments
16 Conclusion and Key FindingsList of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (M USD)
Table 4. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (M USD)
Table 5. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Comparison by Region (M USD)
Table 6. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) as of 2024)
Table 11. Global Market Drugs for Duchenne Muscular Dystrophy (DMD) Average Price (USD/MT) of Key Manufacturers (2020-2025)
Table 12. Manufacturers Drugs for Duchenne Muscular Dystrophy (DMD) Manufacturing Sites and Area Served
Table 13. Manufacturers Drugs for Duchenne Muscular Dystrophy (DMD) Product Type
Table 14. Global Drugs for Duchenne Muscular Dystrophy (DMD) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Drugs for Duchenne Muscular Dystrophy (DMD) Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 25. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Comparison by Region (M USD)
Table 26. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2020-2033) & (M USD)
Table 27. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Region (2020-2033)
Table 28. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region (2020-2033) & (K MT)
Table 29. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region (2020-2033)
Table 30. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2033) & (M USD)
Table 31. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country (2020-2033) & (K MT)
Table 32. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Type (K MT)
Table 33. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (M USD)
Table 34. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Type (2020-2033)
Table 35. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Type (2020-2033)
Table 36. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Application (K MT)
Table 37. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (M USD)
Table 38. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Application (2020-2033)
Table 39. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Application (2020-2033)
Table 40. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2033) & (M USD)
Table 41. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country (2020-2033) & (K MT)
Table 42. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Type (K MT)
Table 43. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (M USD)
Table 44. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Type (2020-2033)
Table 45. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Type (2020-2033)
Table 46. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Application (K MT)
Table 47. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (M USD)
Table 48. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Application (2020-2033)
Table 49. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Application (2020-2033)
Table 50. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2025) & (M USD)
Table 51. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country (2020-2025) & (K MT)
Table 52. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Type (K MT)
Table 53. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (M USD)
Table 54. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Type (2020-2033)
Table 55. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Type (2020-2025)
Table 56. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Application (K MT)
Table 57. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (M USD)
Table 58. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Application (2020-2033)
Table 59. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Application (2020-2025)
Table 60. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2033) & (M USD)
Table 61. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country (2020-2033) & (K MT)
Table 62. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Type (K MT)
Table 63. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (M USD)
Table 64. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Type (2020-2033)
Table 65. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Type (2020-2033)
Table 66. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Application (K MT)
Table 67. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (M USD)
Table 68. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Application (2020-2033)
Table 69. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Application (2020-2033)
Table 70. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2033) & (M USD)
Table 71. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country (2020-2033) & (K MT)
Table 72. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Type (K MT)
Table 73. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (M USD)
Table 74. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Type (2020-2033)
Table 75. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Type (2020-2033)
Table 76. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Application (K MT)
Table 77. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (M USD)
Table 78. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Application (2020-2033)
Table 79. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Application (2020-2033)
Table 80. Global Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) by Region(2020-2025)
Table 81. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million) by Region (2020-2025)
Table 82. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Region (2020-2025)
Table 83. Global Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 84. North America Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 85. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 86. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 87. China Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 88. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Type (K MT)
Table 89. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (M USD)
Table 90. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Type (2020-2033)
Table 91. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Type (2020-2033)
Table 92. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Type (2020-2033)
Table 93. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Type (2020-2033)
Table 94. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Application
Table 95. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application(M USD)
Table 96. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Application (2020-2033) & (K MT)
Table 97. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application (2020-2033)
Table 98. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2020-2033) & (M USD)
Table 99. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2020-2033)
Table 100. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Growth Rate by Application (2020-2033)
Table 101. Sarepta Therapeutics Basic Information
Table 102. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 103. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 104. Sarepta Therapeutics Business Overview
Table 105. Sarepta Therapeutics SWOT Analysis
Table 106. Sarepta Therapeutics Recent Developments
Table 107. PTC Therapeutics Basic Information
Table 108. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 109. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 110. PTC Therapeutics Business Overview
Table 111. PTC Therapeutics SWOT Analysis
Table 112. PTC Therapeutics Recent Developments
Table 113. Pfizer Basic Information
Table 114. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 115. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 116. Pfizer Business Overview
Table 117. Pfizer SWOT Analysis
Table 118. Pfizer Recent Developments
Table 119. Bristol-Myers Squibb Basic Information
Table 120. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 121. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 122. Bristol-Myers Squibb Business Overview
Table 123. Bristol-Myers Squibb Recent Developments
Table 124. Italfarmaco Basic Information
Table 125. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 126. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 127. Italfarmaco Business Overview
Table 128. Italfarmaco Recent Developments
Table 129. Santhera Pharmaceuticals Basic Information
Table 130. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 131. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 132. Santhera Pharmaceuticals Business Overview
Table 133. Santhera Pharmaceuticals Recent Developments
Table 134. WaVe life Science Basic Information
Table 135. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 136. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 137. WaVe life Science Business Overview
Table 138. WaVe life Science Recent Developments
List of Figures
Figure 1. Product Picture of Drugs for Duchenne Muscular Dystrophy (DMD)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD), 2024-2033
Figure 5. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) (2020-2033)
Figure 6. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Drugs for Duchenne Muscular Dystrophy (DMD) Product Life Cycle
Figure 13. Drugs for Duchenne Muscular Dystrophy (DMD) Sales Share by Manufacturers in 2024
Figure 14. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Manufacturers in 2024
Figure 15. Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Drugs for Duchenne Muscular Dystrophy (DMD) Average Price (USD/MT) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in 2024
Figure 18. Industry Chain Map of Drugs for Duchenne Muscular Dystrophy (DMD)
Figure 19. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market PEST Analysis
Figure 20. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Regional Market Development Potential
Figure 26. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region
Figure 27. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Region (2020-2033)
Figure 28. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region (2020-2033)
Figure 29. North American Market Snapshot
Figure 30. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 31. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 32. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Country
Figure 33. USA Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 34. USA Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 35. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) and Growth Rate (2020-2033)
Figure 36. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) and Growth Rate (2020-2033)
Figure 37. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Sales (Units) and Growth Rate (2020-2033)
Figure 38. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) and Growth Rate (2020-2033)
Figure 39. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD)by Type
Figure 40. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Application
Figure 41. Europe Market Snapshot
Figure 42. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 43. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 44. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Country
Figure 45. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 46. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 47. France Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 48. France Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 49. U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 50. U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 51. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 52. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 53. Spain Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 54. Spain Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 55. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Type
Figure 56. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Application
Figure 57. Asia-Pacific Market Snapshot
Figure 58. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 59. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 60. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Country
Figure 61. China Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 66. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 67. India Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 68. India Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 69. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 70. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 71. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Type
Figure 72. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Application
Figure 73. South America Market Snapshot
Figure 74. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 75. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 76. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Country
Figure 77. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 78. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 79. Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 80. Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 81. Columbia Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 82. Columbia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 83. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Type
Figure 84. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Application
Figure 85. Middle East and Africa Market Snapshot
Figure 86. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 87. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 88. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Country
Figure 89. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 90. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 91. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 92. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 93. Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 94. Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 95. Nigeria Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 96. Nigeria Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 97. South Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2033) & (K MT)
Figure 98. South Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 99. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Type
Figure 100. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Application
Figure 101. Global Drugs for Duchenne Muscular Dystrophy (DMD) Production Market Share by Region (2020-2025)
Figure 102. North America Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) Growth Rate (2020-2025)
Figure 103. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) Growth Rate (2020-2025)
Figure 104. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) Growth Rate (2020-2025)
Figure 105. China Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) Growth Rate (2020-2025)
Figure 106. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 107. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (M USD)
Figure 108. Sales Market Share of Drugs for Duchenne Muscular Dystrophy (DMD) by Type (2020-2033)
Figure 109. Sales Market Share of Drugs for Duchenne Muscular Dystrophy (DMD) by Type in 2024
Figure 110. Market Size Share of Drugs for Duchenne Muscular Dystrophy (DMD) by Type (2020-2033)
Figure 111. Market Size Share of Drugs for Duchenne Muscular Dystrophy (DMD) by Type in 2024
Figure 112. Global Drugs for Duchenne Muscular Dystrophy (DMD) Price (USD/MT) by Type (2020-2033)
Figure 113. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 114. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application(M USD)
Figure 115. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application
Figure 116. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application (2020-2033)
Figure 117. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application in 2024
Figure 118. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2020-2033)
Figure 119. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application in 2024
Figure 120. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Growth Rate by Application (2020-2033)